FDA Faces Critical Juncture in Approving New Gene Therapies, Warns Former Commissioner

Hundreds of individualized treatments for rare diseases could become available over the next decade, but their path to approval hinges on the Food and Drug Administration’s ability to navigate the complexities of these novel therapeutics, according to Robert Califf, M.D., former FDA commissioner.

The Promise of Bespoke Gene Therapies

New, highly personalized gene therapies offer potential breakthroughs for patients with rare diseases, often targeting small patient populations. Califf highlighted the aggregate promise of these therapies, suggesting that even treatments for limited numbers of individuals could have a significant impact if properly assessed and approved by the agency. He made these remarks at STAT’s Breakthrough Summit East on Thursday.

Potential Roadblocks and the Demand for Careful Regulation

However, Califf cautioned that failure to effectively regulate these new treatments could lead to a standstill in innovation, potentially delaying progress for years. “But if we don’t receive this right, we could end up in a dead end that sets things back by a number of years,” he stated.

Focus on Evidence-Based Policy

Califf also noted concerns regarding the direction of health policy within the Department of Health and Human Services (HHS), suggesting a shift towards policy-based evidence rather than evidence-based policy. This shift, he implied, could further complicate the FDA’s ability to craft sound decisions regarding these complex therapies.

Califf’s Background and Expertise

Robert Califf, M.D., is an Instructor in Medicine at Duke University School of Medicine and previously served as the Commissioner of the U.S. Food and Drug Administration. He has been a prominent voice in discussions surrounding health innovation and regulatory policy. He also spoke at the STAT Breakthrough Summit West 2025, discussing the impact of AI and emerging tech on health innovation. His previous remarks at the 2022 NORD Breakthrough Summit emphasized the critical role of patient involvement in the FDA’s efforts, particularly in the realm of rare diseases.

Looking Ahead

The FDA now faces a critical period as it develops frameworks for evaluating and approving these individualized gene therapies. The agency’s decisions will not only impact the lives of patients with rare diseases but also shape the future of medical innovation.